Development progress Statute of the combined study of DFP-10917 with Venetoclax

Following the previous information on December 9. In 2024, we are pleased to share the most recent development status.

Regarding the Phase I/II Clinical Trial of DFP-10917 in combination with venevitoclax (VEN) in Patients with Acute Myeloid Leukemia (AML) in Second Therapy (NCT06382168), The Data Management Committee (DMC) Has Approved The Tolebility of All SiX Patients I (dose Finding) Portion of the Phase I/II Study, and We have a Moving to the Phase II Portion of the Trial for Effective Testing, on 28^Th February 2025. We are pleased to inform that we already have more potential patients waiting to participate in the trial.

Please consider our own innovative approach to miserable cancer patients and contact it.

View the source version on businesswire.com: https://www.businesswire.com/news/home/20250228414852/en/

Contacts:

question

Yasundo Yamasaki, PhD.

Director, business development

Delta-Fly Pharma, Inc.

Central Headquarters: Tokushima 771-0117, Japan

Phone: +81-3-6231-1278

E-mail: [email protected]
Main page: